Rhythm Pharmaceuticals' Setmelanotide Fails Primary Endpoints in Phase 3 EMANATE Trial — Rhythm Pharmaceuticals, Inc.

Event summary

Rhythm Pharmaceuticals' Phase 3 EMANATE trial for setmelanotide failed to meet primary endpoints in four substudies.
Post hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 (NCOA1) substudies at 52 weeks.
No new safety signals were observed, with common adverse events including skin hyperpigmentation and injection site reactions.
Rhythm plans to continue analyzing EMANATE data and evaluate next-generation MC4R agonists bivamelagon and RM-718.

The big picture

Rhythm Pharmaceuticals' setmelanotide, approved for specific genetic obesities, faced a setback as its Phase 3 EMANATE trial did not meet primary endpoints. The company's focus on rare neuroendocrine diseases and the potential of next-generation MC4R agonists will be crucial in determining its future trajectory. The mixed results highlight the challenges in developing targeted therapies for genetically driven obesity.

What we're watching

Clinical Development Paths: Whether Rhythm can leverage post hoc analyses to justify continued development of setmelanotide for specific genetic obesities.
Next-Generation Agonists: The pace at which Rhythm advances bivamelagon and RM-718 in rare genetically driven obesity indications.
Regulatory Strategy: How Rhythm will navigate regulatory pathways given the mixed trial results.